Investor FAQs

Investor FAQs

Show All
What is acromegaly?
Please click here
How is acromegaly currently treated?
Please click here
What is the commercial opportunity for MYCAPSSA?
Please click here
Why does Chiasma expect the MYCAPSSA commercial launch will be a differentiated rare disease launch?
Please click here
What is Chiasma’s patent position on MYCAPSSA?
Please click here
Can Chiasma describe the MYCAPSSA label?
Please click here
How much will MYCAPSSA cost and will healthcare insurers provide coverage for patients?
Please click here
Does Chiasma have a patient access or support program?
Please click here
Chiasma was supposed to present data at The Endocrine Society (ENDO) and the American Association of Endocrinologist (AACE) conferences in 2020 but both conferences were cancelled. Where can I find that data?
Please click here
How does the Chiasma OPTIMAL phase 3 trial differ or compare to the MPOWERED Phase 3 trial?
Please click here
When was Chiasma founded?
Chiasma was incorporated in the State of Delaware in 2001.
Where is Chiasma's corporate headquarters?
Chiasma, Inc.
140 Kendrick Street
Building C, East, 1st Floor
Needham, MA 02494
On what stock exchange are Chiasma’s shares traded, and what is the ticker symbol?
Chiasma’s stock is traded on the NASDAQ Global Market under the symbol CHMA.
What is Chiasma’s CUSIP number?
The CUSIP number for Chiasma’s common stock is 16706W 102 .
When did Chiasma go public?
Chiasma’s initial public offering was on July 16, 2015.
Does Chiasma have a dividend reinvestment program?
Chiasma does not currently offer a dividend reinvestment program, and does not expect to declare or pay dividends on our common stock in the foreseeable future.
Does Chiasma have a direct stock purchase plan?
Chiasma does not currently have a direct stock purchase plan.
Who is Chiasma's transfer agent?
The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company. The transfer agent and registrar’s address is 59 Maiden Lane, New York, NY 10038, and its telephone number is (212) 936-5100.
Whom do I contact with questions about my stock certificates?
If you have misplaced or have a question about your stock certificates, please contact Chiasma’s transfer agent, American Stock Transfer & Trust Company. There may be a fee involved for replacing lost stock certificates.
What is Chiasma’s fiscal year?
Chiasma’s fiscal year begins January 1 and ends December 31.
Who are Chiasma's legal counsel and independent auditors?

Our legal counsel is:
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02110
(617) 570-1000

Our independent auditor is:
Deloitte & Touche LLP
200 Berkeley Street
7th Floor
Boston, MA 02116

How can I view documents Chiasma has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financials & Filings section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
How can I request additional information or materials from the company?

For financial or stock information and history, please refer to the Financials & Filings and Stock Information sections of the IR website. To request additional information or materials, please send us a request through the Information Requests page, which can be found under the Contact section of the IR site.

 

Will Mycapssa data in Symphony be a reliable source? Did Chiasma opt in to allowing their spec pharms to share data?

Chiasma is distributing Mycapssa through a limited network of specialty pharmacies which, for competitive reasons, are not permitted to share product sales/utilization data with any third-party data reporting provider, such as IQVIA or Symphony. Given this, we do not believe MYCAPSSA data reported by third-party sources would be reliable.

As a reminder, Chiasma is currently executing the first phase of a staged launch with a smaller customer-facing team, which we previously disclosed is about half the size of what we expect at full-strength. In 2020, the focus of this team is to educate select HCPs and patients about the treatment burden from injectables and the benefits of Mycapssa, negotiate broad access with payers and adapt to remote selling in the COVID-19 environment, with the goal of building a solid foundation for the next phase of our launch in 2021.

Do you have another question that hasn’t been answered?
Please fill out the form here: Information Request

Shareholder Tools